Loading...

Unichem Laboratories

BSE:506690
Snowflake Description

Second-rate dividend payer with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
506690
BSE
₹14B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Unichem Laboratories Limited manufactures and sells pharmaceutical formulations in India, the United States, Canada, Brazil, and other Latin American markets. The last earnings update was 290 days ago. More info.


Add to Portfolio Compare Print
506690 Share Price and Events
7 Day Returns
-0.5%
BSE:506690
0.2%
IN Pharmaceuticals
1.1%
IN Market
1 Year Returns
-25.8%
BSE:506690
0.8%
IN Pharmaceuticals
-0.9%
IN Market
506690 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Unichem Laboratories (506690) -0.5% 1% -7% -25.8% -18.7% -12.6%
IN Pharmaceuticals 0.2% 0.8% 4.1% 0.8% -11.1% 36.6%
IN Market 1.1% 1.8% 5.7% -0.9% 41% 72.2%
1 Year Return vs Industry and Market
  • 506690 underperformed the Pharmaceuticals industry which returned 0.8% over the past year.
  • 506690 underperformed the Market in India which returned -0.9% over the past year.
Price Volatility
506690
Industry
5yr Volatility vs Market
Related Companies

506690 Value

 Is Unichem Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Unichem Laboratories. This is due to cash flow or dividend data being unavailable. The share price is ₹193.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Unichem Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Unichem Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:506690 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in INR ₹-14.67
BSE:506690 Share Price ** BSE (2019-04-18) in INR ₹193.25
India Pharmaceuticals Industry PE Ratio Median Figure of 112 Publicly-Listed Pharmaceuticals Companies 20.2x
India Market PE Ratio Median Figure of 2,736 Publicly-Listed Companies 16.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Unichem Laboratories.

BSE:506690 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:506690 Share Price ÷ EPS (both in INR)

= 193.25 ÷ -14.67

-13.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unichem Laboratories is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
  • Unichem Laboratories is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Unichem Laboratories's expected growth come at a high price?
Raw Data
BSE:506690 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Pharmaceuticals Industry PEG Ratio Median Figure of 32 Publicly-Listed Pharmaceuticals Companies 1.39x
India Market PEG Ratio Median Figure of 584 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Unichem Laboratories, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Unichem Laboratories's assets?
Raw Data
BSE:506690 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in INR ₹381.03
BSE:506690 Share Price * BSE (2019-04-18) in INR ₹193.25
India Pharmaceuticals Industry PB Ratio Median Figure of 133 Publicly-Listed Pharmaceuticals Companies 1.88x
India Market PB Ratio Median Figure of 3,627 Publicly-Listed Companies 1.11x
BSE:506690 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:506690 Share Price ÷ Book Value per Share (both in INR)

= 193.25 ÷ 381.03

0.51x

* Primary Listing of Unichem Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unichem Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Unichem Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Unichem Laboratories has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

506690 Future Performance

 How is Unichem Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unichem Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.5%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Unichem Laboratories expected to grow at an attractive rate?
  • Unable to compare Unichem Laboratories's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Unichem Laboratories's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Unichem Laboratories's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BSE:506690 Future Growth Rates Data Sources
Data Point Source Value (per year)
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 18.6%
India Market Revenue Growth Rate Market Cap Weighted Average 11.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:506690 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:506690 Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BSE:506690 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-03-31 8,180 -1,123 -1,331
2017-12-31 15,855 405
2017-03-31 6,977 682 -707
2016-03-31 13,327 1,117 1,081

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Unichem Laboratories is high growth as no earnings estimate data is available.
  • Unable to determine if Unichem Laboratories is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:506690 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Unichem Laboratories Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:506690 Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BSE:506690 Past Financials Data
Date (Data in INR Millions) EPS *
2018-03-31 -14.67
2017-12-31 4.46
2017-03-31 -7.78
2016-03-31 11.90

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Unichem Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 506690’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Unichem Laboratories's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Unichem Laboratories's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Unichem Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Unichem Laboratories has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

506690 Past Performance

  How has Unichem Laboratories performed over the past 5 years?

  • Unichem Laboratories's last earnings update was 290 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Unichem Laboratories's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Unichem Laboratories does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Unichem Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Unichem Laboratories's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Unichem Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Unichem Laboratories Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:506690 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 8,180.04 -1,330.98 2,122.97
2017-12-31 15,855.14 405.32 4,258.30 585.28
2017-03-31 6,977.14 -707.23 1,805.59
2016-03-31 13,326.52 1,081.07 3,311.22 416.32
2015-03-31 12,017.93 753.90 3,004.24 446.48
2014-03-31 11,334.48 1,281.62 4,379.54 505.37
2013-03-31 10,808.03 1,132.26 4,024.62 354.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Unichem Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Unichem Laboratories has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Unichem Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Unichem Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Unichem Laboratories has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

506690 Health

 How is Unichem Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Unichem Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unichem Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Unichem Laboratories's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Unichem Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 15.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Unichem Laboratories Company Filings, last reported 1 year ago.

BSE:506690 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 26,800.84 1,507.23 15,619.56
2017-12-31 35,762.40 2,067.28 28,054.13
2017-03-31 10,636.20 980.75 192.11
2016-03-31 9,543.33 359.06 325.68
2015-03-31 8,675.20 219.72 661.57
2014-03-31 8,166.09 256.84 620.68
2013-03-31 7,270.72 270.64 615.10
  • Unichem Laboratories's level of debt (5.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.7% vs 5.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Unichem Laboratories's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Unichem Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Unichem Laboratories has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

506690 Dividends

 What is Unichem Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.59%
Current annual income from Unichem Laboratories dividends.
If you bought ₹2,000 of Unichem Laboratories shares you are expected to receive ₹52 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unichem Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.5%).
  • Unichem Laboratories's dividend is above the markets top 25% of dividend payers in India (1.94%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:506690 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 69 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1400 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:506690 Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
BSE:506690 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-05-29 5.000 2.376
2017-05-30 3.000 1.056
2016-03-09 2.000 0.755
2015-06-15 2.000 0.814
2015-05-11 2.000 1.048
2014-06-18 4.000 1.835
2013-07-19 4.500 2.411
2012-09-28 3.000 1.678
2011-05-16 4.000 2.850
2010-10-18 4.000 1.914
2010-05-10 4.000 2.197
2009-10-22 3.200 2.440
2009-05-21 3.200 3.572
2009-04-20 2.400 3.525

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Unichem Laboratories's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Unichem Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Unichem Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Unichem Laboratories has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

506690 Management

 What is the CEO of Unichem Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Prakash Mody
COMPENSATION ₹14,331,000
AGE 65
TENURE AS CEO 15.8 years
CEO Bio

Dr. Prakash Amrut Mody has been Chairman of the Board and Managing Director of Unichem Laboratories Limited since July 1, 2003. Dr. Mody has a rich experience in the field of marketing, research and production. Dr. Mody has been a Non Executive Independent Director of Kewal Kiran Clothing Limited since November 14, 2005. He serves as a Director of Unichem Laboratories Limited. He serves on the Board of all Subsidiary Companies of Unichem. He serves as the Chairman of the Board of the Industrial pharmacy division of the Indian Pharmaceutical Association. He served as Vice President of the Indian Pharmaceutical Association. He serves as a Member of National committee on drugs and pharmaceuticals of the Confederation of Indian Industry. He serves as on the Executive Committee of the Indian Drug Manufacturers Association. He serves as a Member of the Young President' Organisation Inc., an international organization for young President. He serves as a Member of the Senate - SNDT Women's University and Rotary Club of Bombay Mid-Town and is also involved in many other social activities. Dr. Mody is a doctorate (Ph.D.) in Organic Medicinal Chemistry from the University of Mumbai. He perceived marketing management from Jamnalal Bajaj Institute of Management Studies, University of Mumbai. He is a Graduate Alumni of Harvard Business School having undergone the Owner President' Management Program.

CEO Compensation
  • Prakash's compensation has been consistent with company performance over the past year.
  • Prakash's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Unichem Laboratories management team in years:

6.7
Average Tenure
60
Average Age
  • The average tenure for the Unichem Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Prakash Mody

TITLE
Chairman & MD
COMPENSATION
₹14M
AGE
65
TENURE
15.8 yrs

Neema Thakore

TITLE
Head of Legal
COMPENSATION
₹14M
AGE
59
TENURE
3.9 yrs

Dilip Kunkolienkar

TITLE
Director of Technical & Whole-Time Director
COMPENSATION
₹8M
AGE
67
TENURE
1 yrs

Prasad Joshi

TITLE
Vice President of Human Resources & ER
COMPENSATION
₹7M
AGE
60
TENURE
10.8 yrs

Vinod Behl

TITLE
Head of Projects & Investments
COMPENSATION
₹2M
AGE
68

Bhagwat Dhingra

TITLE
Chief Executive of Domestic Pharma
COMPENSATION
₹14M
AGE
55
TENURE
6.7 yrs

Scott Delaney

TITLE
President of North America & CEO of North America
AGE
49
TENURE
0.8 yrs

P. Deshpande

TITLE
Vice President of Chemical of Research and Development
COMPENSATION
₹593K
AGE
63

Supriya Mody

TITLE
Associate Vice President of International Business
COMPENSATION
₹4M

Gajendra Ghanekar

TITLE
Vice President of Commercial
COMPENSATION
₹6M
AGE
59
TENURE
18.4 yrs
Board of Directors Tenure

Average tenure and age of the Unichem Laboratories board of directors in years:

14.9
Average Tenure
66
Average Age
  • The average tenure for the Unichem Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Prakash Mody

TITLE
Chairman & MD
COMPENSATION
₹14M
AGE
65
TENURE
15.8 yrs

Dilip Kunkolienkar

TITLE
Director of Technical & Whole-Time Director
COMPENSATION
₹8M
AGE
67
TENURE
1 yrs

Prafull Shah

TITLE
Non-Executive & Independent Director
COMPENSATION
₹2M
AGE
80
TENURE
39.7 yrs

Prafull Sheth

TITLE
Non-Executive & Independent Director
COMPENSATION
₹1M
TENURE
15.6 yrs

Anand Mahajan

TITLE
Independent Director
COMPENSATION
₹550K
AGE
65
TENURE
14.3 yrs

B. Murthy

TITLE
Independent Director
COMPENSATION
₹970K
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Unichem Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Unichem Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

506690 News

Simply Wall St News

506690 Company Info

Description

Unichem Laboratories Limited manufactures and sells pharmaceutical formulations in India, the United States, Canada, Brazil, and other Latin American markets. It offers pharma products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients. The company was founded in 1944 and is based in Mumbai, India.

Details
Name: Unichem Laboratories Limited
506690
Exchange: BSE
Founded: 1944
₹13,601,563,062
70,383,250
Website: http://www.unichemlabs.com
Address: Unichem Laboratories Limited
Unichem Bhavan,
Prabhat Estate,
Mumbai,
Maharashtra, 400102,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 506690 Equity Shares Mumbai Stock Exchange IN INR 26. Aug 1994
NSEI UNICHEMLAB Equity Shares National Stock Exchange of India IN INR 26. Aug 1994
Number of employees
Current staff
Staff numbers
0
Unichem Laboratories employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 12:30
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2018/05/29
Last earnings filing: 2018/07/03
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.